The Week Ahead In Biotech: Conferences, Clinical Trial Results, IPOs And More

A bit of a lull took place in the biotech space ahead of earnings season; IPO activity was non-existent, but there was some action on account of clinical trial results.

Here's a look at the upcoming week's catalytic events.

Conferences

• 25th Annual Congress on Cardiology and Medical Interventions: July 16-17, Atlanta, Georgia
• 2nd International Conference on Medical and Clinical Microbiology: July 16-17, Melbourne, Australia
• 25th World Congress on Neurology and Neurodisorders: July 16-17, Melbourne, Australia
• 8th World Congress on Breast Cancer & Therapies: July 16-17, Melbourne, Australia
• 2nd World Congress on Radiology and Oncology: July 16-17, Dubai
• 7th World Congress on Addictive Disorders & Addiction Therapy: July 16-18, London
• 29th International Conference on Public Mental Health and Neuroscience: July 16-18, Dubai
• 4th Annual Conference on Preventive Oncology: July 18-19, Atlanta, Georgia
• 4th Annual Conference on Gynecologic Oncology, Reproductive Disorders, Maternal-Fetal Medicine & Obstetrics: July 18-19, Atlanta, Georgia
• 11th World Congress on Orthopedics, Rheumatology & Sports Medicine: July 18-19, Sydney, Australia
• 64th Annual International Society on Thrombosis and Haemostasis  Scientific and Standardization Committee Meeting: July 18-21, Dublin, Ireland

Clinical Trial Results

Catalyst Biosciences Inc CBIO is set to release interim Phase 2 data for its hemophilia treatment marzeptacog alfa at the ISTH SSC meeting Wednesday.

Earnings

Monday, July 16

Avid Bioservices Inc CDMO

Thursday, July 19

Intuitive Surgical, Inc. ISRG

See Also: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

IPO

Allakos, a clinical stage biotech company developing therapy for treating eosinophil and mast cell-related diseases, is set to offer 6 million shares with an expected price range of $15-$17. The shares are to be listed on the Nasdaq under the ticker symbol ALLK.

Constellation Pharmaceuticals will offer 5.34 million shares in an IPO with an estimated price range of $14-$15. The company, which develops therapies to tackle cancers associated with abnormal gene expression or drug resistance, seeks to list its shares on the Nasdaq under the ticker symbol CNST.

Crinetics Pharmaceuticals, which develops therapies for rare endocrine diseases and endocrine-related tumors, is planning a 5-million-share IPO, with the shares expected to be priced between $15 and $17. The shares will be listed on the Nasdaq under the ticker symbol CRNX.

Oncolytic immunotherapy company Replimune Group is due to offer 6.7 million shares in an IPO, with the price estimated in a range of $14-$16. The shares are to be listed on the Nasdaq under the ticker symbol REPL.

Rubius Therapeutics is set to offer 9.53 million shares in an IPO expected to be priced between $20 and $22. The company is looking to list its shares on the Nasdaq under the ticker symbol RUBY.

IPO Quiet Period Expirations

• Eidos Therapeutics Inc EIDX
• Kezar Life Sciences Inc KZR
• Aptinyx Inc APTX
• Xeris Pharmaceuticals Inc XERS
• Magenta Therapeutics Inc MGTA
• Avrobio Inc AVRO
• Autolus Therapeutics Ltd – ADR AUTL